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Mega trials in COPD — clinical data analysis and design issues
Wielkie badania kliniczne w POChP — planowanie badań i analiza wyników
Abstract
The TORCH and UPLIFT randomised controlled trials have provided important data on the benefits of COPD treatments, but
also some lessons in study design and data analysis that we will here review.
Firstly, it is fundamental that the study question be answerable by the study design. The question in the TORCH study was
aimed at a comparison with ‘usual care’, but the placebo group was not ‘usual care’. Secondly, TORCH and UPLIFT were
among the first trials to follow the intent-to-treat principle, fundamental to avoid bias in randomised trials. However, this
principle was followed for the mortality outcome, but not for lung function, so that the findings related to lung function
decline are subject to bias from regression to the mean. Finally, a re-analysis of the TORCH study (performed to fully exploit
the data as a 2 × 2 factorial trial) shows that a mortality benefit is entirely accounted for by the effect of the long-acting
b-agonist salmeterol, with no effect attributable to the inhaled corticosteroid fluticasone component of the combination
therapy. Together, these data suggest that long-acting bronchodilators, including anticholinergics such as tiotropium and
beta-agonists, are associated with lower mortality of patients with COPD, but not inhaled corticosteroids. With COPD one of
the major causes of morbidity and mortality worldwide, mega trials such as TORCH and UPLIFT are much needed, but must
achieve the utmost scientific rigour in their design and analysis.
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Streszczenie
Randomizowane, kontrolowane badania nad lekami TORCH i UPLIFT dostarczyły istotnych informacji o korzyściach z ich
stosowania u chorych na POChP, a także były lekcją dotyczącą wpływu planowania badań i analizy wyników na jakość
uzyskanych wyników.
Celem badania TORCH było porównanie stosowanego leczenia z leczeniem rutynowym, jednakże grupa placebo nie otrzymy-
wała rutynowego leczenia.
TORCH i UPLIFT były jednymi z pierwszych badań, w których analiza wyników oparta była na zasadzie „intention-to-treat”, bardzo
ważnej dla uniknięcia wątpliwości w badaniach randomizowanych. Jednakże ta zasada obejmowała tylko analizę umieralności, ale już
nie czynności płuc. Z tego powodu ta druga ulegała wpływowi zjawiska regresji do średniej. Natomiast dodatkowa analiza wyników
badania TORCH wykazała, że korzystny wpływ na umieralność był spowodowany wyłącznie długodziałającym lekiem rozszerzającym
oskrzela bez wpływu na obniżenie umieralności na POChP wziewnego steroidu w leczeniu skojarzonym. Łącznie, wyniki tych badań
sugerują, że obniżenie umieralności na POChP jest związane z długodziałającymi  lekami rozszerzającymi oskrzela, w tym antycholi-
nergikami, takimi jak tiotropium i agonistami  receptorów b,  a nie z działaniem wziewnych kortykosteroidów. Przewlekła obturacyj-
na choroba płuc jest jedną z głównych przyczyn chorobowości i umieralności na świecie. Wielkie badania kliniczne, takie jak
TORCH i UPLIFT, są potrzebne, ale powinny być prowadzone z najwyższą naukową starannością w planowaniu i analizie wyników.
Słowa kluczowe: skuteczność leku, metody, przewlekła obturacyjna choroba płuc, wziewne kortykosteroidy,
antycholinergiki, długodziałające b-agoniści
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FEV1 in patients with COPD who were permitted
therapy other than other inhaled anticholinergic
drugs, according to current COPD guidelines” [2].
Does the design of each study allow addres-
sing its study question? One of the challenges in
designing such studies is that the drugs being eva-
luated were already on the market; so some study
patients may already be using the study drugs.
Here, the study protocol required patients to stop
this treatment prior to randomisation. For exam-
ple, the TORCH trial involved 6,112 moderate to
severe COPD patients randomised to one of four
treatment groups (fluticasone, salmeterol, both, or
a placebo) followed for three years. Any patients
already using inhaled corticosteroids or long-ac-
ting beta-agonists prior to randomisation had to cease
these medications. In particular, of the 1,524 patients
randomised to a placebo, 22% had to stop inhaled
corticosteroid therapy, 8% to cease taking long-
acting beta-agonists, and 29% the combination of
inhaled corticosteroids with a long-acting beta-ago-
nist. Thus, nearly 60% of patients randomised to
a placebo had to stop these two forms of treatment.
Can we then claim that COPD patients who have
been on maintenance therapy with a LABA and/or
ICS, and who are made to stop these medications
and replace them with placebos for three years re-
present “usual care”? This seems unlikely. So, it can
be said that the design of the TORCH trial could not
permit the study to answer its question, namely to
assess the effect of combination salmeterol/flutica-
sone relative to “usual care”.
In the UPLIFT study, 5,993 patients with
COPD were randomly assigned to tiotropium
(n = 2,987) or a placebo (n = 3,006) for four years.
Patients were required to cease taking their anti-
cholinergics at the time of randomisation, but co-
uld continue all other maintenance treatment du-
ring the four-year follow-up. Thus, in UPLIFT, 44%
of the patients randomised to a placebo stopped
their short-acting anticholinergic, which could be
replaced by another rescue medication, while only
2% of the patients put on placebo were already on
the long-acting anticholinergic tiotropium and had
to stop it at randomisation. Consequently, we can
say that the design of the UPLIFT trial generally
permitted the answering of its study question; na-
mely to assess the effect of adding tiotropium to
the existing treatment of COPD patients.
In fact, the various previous trials of ICS in
COPD were conducted, at least in part, among pa-
tients already using these medications before ran-
domisation. The proportion of patients who were
previous users of these drugs and were required to
cease using them at the time of randomisation in
Introduction
The TORCH and UPLIFT mega-trials have
been study landmarks in the field of chronic ob-
structive pulmonary disease (COPD) therapeutics.
They have advanced our knowledge as to the po-
tential benefits of long-acting bronchodilators, in-
cluding long-acting beta-agonists and the long-ac-
ting anticholinergic tiotropium, as well as of inha-
led corticosteroids (ICS), in treating this disease [1,
2]. These mega-trials were important because the
previous randomised controlled trials, that evalu-
ated the effectiveness of inhaled corticosteroids in
particular, reported results that were often contra-
dictory and paradoxical [3, 4]. Generally, these
former studies (which were smaller) found that
inhaled corticosteroids either had no effect, or only
minor beneficial effects on lung function as me-
asured by FEV1, the primary outcome measure,
while several of the studies observed significant
reductions in COPD exacerbation rates associated
with ICS use. A meta-analysis of these trials even
suggested a significant reduction in exacerbations
of approximately 30% [5].
Much of this apparent meta-analysed benefit,
however, resulted from an incorrect, unweighted,
approach to the data analysis of these exacerba-
tions, failing also to incorporate correction for over-
dispersion in their statistical analysis [6]. In addi-
tion, a pooled analysis of data from seven rando-
mised trials involving more than 5,000 patients
reported a significant 27% reduction in all-cause
mortality associated with ICS use [7].
In view of this confusing background, the
TORCH and UPLIFT mega trials were especially
important to clarify the place of long-acting bron-
chodilators and inhaled corticosteroids in the tre-
atment of patients with COPD.
In this paper, we review some key aspects of
the design and statistical analysis of TORCH and
UPLIFT, and interpret their results in light of the
current recommendations for COPD management.
Study question and design
The a priori question under investigation is the
foundation of a clinical trial, since it will impact
directly on its design and analysis. In the TORCH
trial, the authors: “hypothesised that the combina-
tion of the long-acting beta-agonist salmeterol and
the inhaled corticosteroid fluticasone propionate
would reduce mortality among patients with
COPD, as compared with usual care” [1].
In the UPLIFT trial, the authors: “tested whe-
ther tiotropium would reduce the rate of decline in
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the placebo group varied from 26% in one trial [8]
to as high as 77% in the OPTIMAL trial [9]. This
unusual situation creates a challenge in interpre-
tation. Indeed, among the patients who did not
previously use inhaled corticosteroids, randomi-
sation will lead to the desired comparison betwe-
en patients initiating treatment with ICS, and si-
milar patients who do not. On the other hand,
among the patients who were previously regular
users of inhaled corticosteroids, randomisation
will in fact provide a comparison between patients
who continue to use ICS (patients allocated to ICS
treatment) and patients who discontinue ICS (pa-
tients allocated to a placebo). These different com-
parisons can lead to very different results [10].
Intent to treat: mortality
Before the TORCH and OPTIMAL studies, ran-
domised trials of COPD therapy stopped patient
follow-up at the time they discontinued the study
drug. Thus, any outcome information arising after
the patients had stopped treatment, but before the
planned end of the study follow-up, was not collec-
ted. As such, the fundamental intent-to-treat ana-
lysis for such trials was not possible, since the data
was truncated at the time of drug discontinuation.
While this problem may be trivial in other
diseases, COPD trials characteristically demonstra-
te very high discontinuation rates, often occurring
very early in the trial. Not following patients thro-
ugh to the end, and conducting the data analysis
only until discontinuation of study drugs, will pro-
duce biased results if the reasons for discontinu-
ation are associated with the outcome, and differ
between treatments.
To avoid such bias, the TORCH trial correctly
followed all patients up to the end of the three-year
trial period to ascertain mortality, its primary out-
come, even after discontinuation of the study me-
dications. This was not done, however, for the se-
condary outcomes, including exacerbations, lung
function and health status. This is of concern, be-
cause 44% of patients in the placebo group discon-
tinued treatment, mostly during the first few mon-
ths, compared to 34% in the combination therapy
group. Thus, for the TORCH trial, the intent-to-tre-
at results for mortality are valid; but the results
describing the secondary outcomes, and in parti-
cular exacerbations, may be biased.
To illustrate this bias, a comparison can be
made between the pooled analysis of seven major
randomised trials involving 5,086 patients, that
found a significant 27% reduction in all-cause
mortality with ICS (hazard ratio 0.73; 95% CI: 0.55–
0.96; p = 0.039), and the TORCH trial that found
no reduction whatsoever with fluticasone [1, 7].
The seven trials that comprised the pooled analy-
sis truncated patient follow-up when they discon-
tinued the study drug. The pooled analysis in fact
found no difference in mortality during the first
nine months of follow-up, the time period where
drop-outs were still rare, and thus most randomi-
sed patients were included in the mortality analy-
sis, while the apparent benefit of ICS only became
visible after nine months [11]. On the other hand,
the TORCH trial that followed all patients up for
three years found a hazard ratio of mortality for
fluticasone relative to placebo of 1.06 (95% CI:
0.89–1.27; p = 0.53) [1]. Such a disagreement be-
tween two large mortality studies is probably
a direct result of the follow-up process and a pro-
per intent-to-treat analysis in the TORCH study.
Another aspect of the intent-to-treat analysis
is the time period under study. In the TORCH stu-
dy, the treatment was intended to be taken for three
years and the analysis was based on all deaths oc-
curring exactly during this period. Thus, deaths
that occurred at three years plus one day were cor-
rectly not counted in the analysis. In the UPLIFT trial,
the treatment was taken for four years (1,440 days) so
that the proper intent-to-treat analysis should have
been based on all deaths occurring exactly during
this four-year period (hazard ratio 0.87; 95% CI:
0.76–0.99). However, the study design also invo-
lved a post-study follow-up where, at the end of
the study, all patients were provided with (and
asked to take) 40 µg of ipratropium four times da-
ily and to return for a final assessment 30 days
later. The authors incorrectly based their prima-
ry intent-to-treat analysis of mortality on the de-
aths occurring during the period of four years plus
30 days (1,470 days) which led to a hazard ratio
of 0.89 (95% CI: 0.79–1.02).
Intent to treat: lung function
Decline in lung function over time is a funda-
mental measure of disease progression among pa-
tients with COPD. FEV1 decline was in fact the
primary outcome measure for the UPLIFT and
many other randomised controlled trials evaluating
whether pharmacological treatments could modi-
fy the natural history of COPD. The TORCH trial
also considered this outcome and reported in
a secondary paper that the yearly decline in FEV1
was significantly slower with fluticasone, salme-
terol, or both, compared to a placebo [12, 13].
The TORCH and UPLIFT trials were not desi-
gned for a full intent-to-treat analysis of lung func-
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tion decline, but only measured FEV1 until the
patients discontinued treatment. For example, in
the TORCH trial, of the 6,112 patients in the stu-
dy, the lung function analysis involved only 5,343
subjects with at least one measurement of post-
bronchodilator FEV1 made up to twice yearly du-
ring follow-up. Consequently, 10,133 FEV1 measu-
rements were missing from a possible 36,672 me-
asurements that the study could have yielded.
This may cause bias from regression to the mean
[14, 15].
Such a bias occurs for several reasons. Firstly,
some patients are excluded altogether from the
analysis. Nearly 18% of patients allocated to a pla-
cebo did not contribute a single FEV1 value becau-
se they discontinued placebo before the first six-
month visit when the first FEV1 was measured. It
is likely that these excluded patients would have
had poorer FEV1 values at that first visit had they
been available to be measured. Thus, the slope of
decline in the remaining subjects with better FEV1
values at the first visit is probably exaggerated by
regression to the mean. Secondly, discontinuing
the follow-up of patients who have the initial FEV1
Table 1. Factorial regression analysis of TORCH data to estimate the independent effects of fluticasone and salmeterol on
the three-year incidence of all-cause mortality
Medication allocated
Yes No Adjusted RR (95% CI) p-value
(Deaths/N) (Deaths/N)
Medication
Fluticasone 439/3,067 436/3,045 1.00 (0.89–1.13) 0.9918
Salmeterol 398/3,054 477/3,058 0.83 (0.74–0.95) 0.0043
Figure 1. Depiction of regression to the mean: correlation betwe-
en initial FEV1 value (divided in quartiles) and the change in FEV1
from months 3 to 12 (mean change in each quartile). Patients in
the highest quartile of initial FEV1 values show the largest decline
(119 mL), while patients in the lowest quartile of initial FEV1 valu-
es show an improvement of 32 mL
value measured but are missing some subsequent
values can also alter the slope of decline in FEV1.
In the TORCH study, the placebo patients who di-
scontinued before the end of follow-up had a fa-
ster decline in FEV1 (76 mL/year) than those com-
pleting the trial (54 mL/year) [12]. Here again, the-
se slopes of decline may have been affected by re-
gression to the mean.
To illustrate the regression to the mean phe-
nomenon, and its resulting bias, we used data on
322 subjects from the Canadian OPTIMAL trial,
a three-arm randomised trial of 449 patients with
moderate or severe COPD [9]. For illustration pur-
poses, FEV1 decline was simply measured as the
difference in FEV1 between the 12-month and
three-month visits. The 322 patients had a mean
FEV1 of 1,131 mL at three months, with a change
in FEV1 from three to 12 months of 39 mL. Figure
1 depicts the regression to the mean phenomenon
by showing that patients in the highest quartile of
initial FEV1 values (> 1,440 mL) have the largest
decline (mean decline 119 mL), while the patients in
the lowest quartile of initial FEV1 values (< 770 mL)
in fact show an improvement of 32 mL [15].
To illustrate this impact on the TORCH stu-
dy results, we assumed that the 18% of patients
who were missing from the TORCH placebo gro-
up were more likely to be the sicker patients with
the lowest FEV1. Thus, excluding the 18% of pa-
tients with the lowest FEV1 at visit 1 (< 700 mL)
from the 322 patients, the one-year rate of FEV1
decline among the remaining subjects becomes
52.2 mL; a clear overestimate of the decline from
the 39 mL from the complete data. This is becau-
se the 18% excluded patients have a mean incre-
ase in FEV1 of 40.7 mL.
Factorial analysis of TORCH data
While the TORCH study aimed to compare the
combination of fluticasone and salmeterol with
a placebo, the study also included a fluticasone only
and a salmeterol only arm [1]. This study was thus
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structured as a 2 × 2 factorial design of fluticaso-
ne (yes/no) and salmeterol (yes/no). However,
TORCH was not analysed as a factorial trial, thus
wasting much needed power and denying the re-
ader important information about the independent
contribution of each component of the combina-
tion [10, 16].
As mortality was the only outcome ascertained
in a complete manner for a proper intent-to-treat
analysis, mortality was used to perform the analy-
sis corresponding to a 2 × 2 factorial design. This
factorial analysis must be done using a regression
model, in this case a generalised linear regression
model with a binomial distribution, to estimate the
three-year mortality rate ratio associated with flu-
ticasone and salmeterol [10, 16]. The interaction
term to assess whether there is synergy between
the two drugs was found to be non-significant
(p = 0.32) suggesting that a combination of flutica-
sone and salmeterol is not particularly more effec-
tive than the two components added independen-
tly. Table 1 presents the rates and the independent
effects of fluticasone and salmeterol on mortality,
namely adjusted for each other. While the salme-
terol component is associated with a significant
17% reduction in mortality (rate ratio 0.83; 95%
CI: 0.74–0.95; p = 0.0043), the fluticasone compo-
nent provides no reduction whatsoever (rate ratio
1.00; 95% CI: 0.89–1.13; p = 0.9918) [10].
Conclusion
The randomised controlled trial is and will re-
main the fundamental tool to evaluate the benefit
of COPD treatments. Its proper conduct, however,
including the most rigorous study design and data
analysis, is essential if it is to produce valid results.
The TORCH and UPLIFT trials have provided
important lessons in this context. First and fore-
most, the study question must be answerable by
the study design. We noted that the question in the
TORCH study aimed at a comparison with ‘usual
care’, but the placebo group treatment was not ‘usu-
al care’. TORCH and UPLIFT were among the first
trials in COPD to follow the intent-to-treat princi-
ple, which is fundamental for randomised control-
led trials to avoid bias. However, while this prin-
ciple was followed for the mortality outcome, it
was not followed for lung function decline, where
patients were only measured until they disconti-
nued study medications. As a result, the findings
in both trials relating to lung function decline are
subject to bias from regression to the mean.
Finally, the TORCH study, designed as a 2 × 2
factorial trial to assess the effects of an inhaled
corticosteroid and a long-acting beta-agonist, sho-
uld have exploited fully the data by using the cor-
responding data analysis. This factorial analysis
shows that a mortality benefit is entirely accoun-
ted for by the effect of salmeterol, with no effect
attributable to the inhaled corticosteroid compo-
nent of the combination therapy.
As COPD is one of the major causes of morbidity
and mortality worldwide, mega trials such as TORCH
and UPLIFT are clearly needed, but must be designed
and analysed with the utmost scientific rigour.
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